13F Holdings
中文EN

PFE PFIZER INC

Pharmaceutical Preparations · NYSE · SEC CIK 78003 · Fiscal year ends 12/31

Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.3%
TTM net income YoY-59.0%
TTM EPS YoY-59.3%
Revenue 3-yr CAGR-2.8%
Net income 3-yr CAGR-27.3%

Margins

Gross margin73.4%
Operating margin—
Net margin6.3%
FCF margin18.5%
EBITDA margin—

Returns

ROE4.4%
ROA2.0%
ROIC (approx.)—
Asset turnover0.31x

Leverage & solvency

Liabilities / assets56.3%
Debt / equity0.70x
Current ratio1.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.51x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue3.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-272026Q22026-06-282026Q12026-03-292025Q4*2025-12-312025Q32025-09-282025Q22025-06-292025Q12025-03-302024Q4*2024-12-31
Income statement
Revenue$16.58B$15.03B$14.45B$17.56B$16.65B$14.65B$13.71B$17.76B
Cost of revenue$4.03B$4.09B$3.55B$5.27B$4.17B$3.78B$2.85B$5.91B
Gross profit$12.55B$10.94B$10.90B$12.29B$12.48B$10.88B$10.87B$11.85B
R&D expense$3.02B$2.81B$2.49B$3.21B$2.55B$2.48B$2.20B$3.04B
SG&A expense$3.28B$3.41B$2.96B$4.16B$3.19B$3.42B$3.03B$4.27B
Interest expense$662.00M$667.00M$668.00M$711.00M$652.00M$654.00M$654.00M$739.00M
Pretax income$3.38B-$653.00M$3.17B-$1.64B$3.33B$3.04B$2.79B-$10.00M
Income tax$134.00M-$407.00M$461.00M-$2.00M-$216.00M$141.00M-$189.00M-$421.00M
Net income$3.24B-$248.00M$2.69B-$1.65B$3.54B$2.91B$2.97B$410.00M
EPS (basic)0.57-0.040.47—0.620.510.52—
EPS (diluted)0.56-0.040.47—0.620.510.52—
Dividends declared per share0.000.860.000.860.000.860.000.85
Weighted avg. shares (diluted)5.75B5.70B5.73B—5.71B5.71B5.71B—
Balance sheet
Cash & equivalents$1.82B$976.00M$1.70B$1.14B$1.39B$1.69B$1.48B$1.11B
Short-term investments$9.12B$7.28B$8.19B$9.18B$10.12B$9.53B$13.95B$10.88B
Receivables$14.19B$12.49B$12.59B$11.87B$14.26B$12.08B$11.85B$11.46B
Inventory$10.02B$9.95B$10.67B$10.65B$11.47B$11.67B$10.85B$10.85B
Current assets$45.01B$41.36B$42.82B$42.90B$46.92B$43.70B$45.86B$50.36B
PP&E, net$19.05B$19.03B$19.40B$19.32B$18.88B$18.78B$18.35B$18.39B
Goodwill$71.46B$71.42B$71.41B$71.26B$69.10B$69.00B$68.44B$68.53B
Intangibles$45.96B$47.05B$52.56B$53.73B$51.32B$52.70B$53.98B$55.41B
Total assets$204.54B$201.13B$207.62B$208.16B$208.73B$206.09B$208.03B$213.40B
Current liabilities$31.73B$32.65B$34.35B$36.98B$36.60B$37.73B$36.45B$42.99B
Short-term debt$2.67B$2.70B$3.89B$3.15B$4.30B$4.29B$4.47B$6.95B
Long-term debt$60.00B$60.49B$60.56B$61.64B$57.41B$57.50B$57.64B$57.41B
Total debt$62.67B$63.19B$64.45B$64.80B$61.71B$61.80B$62.11B$64.35B
Total liabilities$115.24B$115.64B$117.21B$121.39B$115.64B$117.08B$117.39B$124.90B
Shareholders' equity$89.00B$85.19B$90.10B$86.48B$92.80B$88.69B$90.34B$88.20B
Net debt$60.85B$62.22B$62.75B$63.65B$60.32B$60.10B$60.63B$63.24B
Cash flow statement
Operating cash flow$5.38B$835.00M$2.62B$5.35B$4.60B-$582.00M$2.33B$6.72B
Capital expenditure$573.00M$533.00M$436.00M$845.00M$602.00M$618.00M$564.00M$917.00M
Free cash flow$4.80B$302.00M$2.18B$4.50B$4.00B-$1.20B$1.77B$5.80B
Investing cash flow-$2.03B$2.11B$785.00M-$6.15B-$2.43B$3.95B$3.27B-$1.62B
Financing cash flow-$2.51B-$3.66B-$2.86B$596.00M-$2.48B-$3.20B-$5.23B-$5.11B
Depreciation & amortization$1.58B$1.62B$1.61B$1.69B$1.66B$1.62B$1.62B$1.79B
Stock-based compensation$362.00M$249.00M$272.00M$225.00M$201.00M$203.00M$170.00M$177.00M

Free plan shows the latest 8 periods; Pro shows all 74 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.